Get the Stockscreener App
4.40
0.68%
-0.03
After Hours:
4.40
Humacyte Inc stock is traded at $4.40, with a volume of 2.56M.
It is down -0.68% in the last 24 hours and down -21.29% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
See More
Previous Close:
$4.43
Open:
$4.44
24h Volume:
2.56M
Relative Volume:
0.85
Market Cap:
$598.31M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-5.0575
EPS:
-0.87
Net Cash Flow:
$-75.59M
1W Performance:
-0.23%
1M Performance:
-21.29%
6M Performance:
-38.46%
1Y Performance:
+71.88%
1-Day Range:
$4.39
$4.74
1-Week Range:
$4.12
$4.74
52-Week Range:
$2.4512
$9.97
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
4.40 | 598.31M | 0 | -110.78M | -75.59M | -0.87 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Humacyte, Inc. Investors to Secure - The Bakersfield Californian
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages - GlobeNewswire
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit - Benzinga
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - GlobeNewswire
Kirby McInerney LLP Reminds Humacyte, Inc. (HUMA) Investors - GlobeNewswire
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
HUMA LAWSUIT ALERT: Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PR Newswire
HUMA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Humacyte, Inc.- HUMA - PR Newswire
Humacyte, Inc. Class Action Lawsuit Alert: Johnson Fistel - GlobeNewswire
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit - PR Newswire
Humacyte (HUMA) Faces Class Action Lawsuit After FDA Inspection Reveals Manufacturing Issues – Hagens Berman - GlobeNewswire
Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital - MarketBeat
HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein - GlobeNewswire
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel - The Bakersfield Californian
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Humacyte, - GlobeNewswire
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Humacyte, Inc. Shareholder Alert: Robbins LLP Reminds Investors of the HUMA Securities Class Action - GlobeNewswire
HUMA DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before January 17, 2025 - The Globe and Mail
HUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Malaysian Reserve
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead - The Bakersfield Californian
Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 – HUMA - Morningstar
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH) - The Manila Times
Humacyte sees success in dual emergency-engineered tissue trials - Yahoo Finance
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc.(HUMA) Shareholders - Marketscreener.com
Faruqi & Faruqi Reminds Humacyte Investors of the Pending - GlobeNewswire
HUMA Deadline to Lead in Securities Fraud Lawsuit is January 17, 2025Contact Kaplan Fox & Kilsheimer LLP - The Globe and Mail
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Humacyte, Inc. (HUMA) - Business Wire
Humacyte director Brady Dougan buys $7,978 in common stock - Investing.com India
ROSEN, LEADING INVESTOR COUNSEL, Encourages Humacyte, Inc. - GlobeNewswire
HUMACYTE, INC. (NASDAQ: HUMA) INVESTOR ALERT: Investors - GlobeNewswire
Insider Buyers At Humacyte Likely Disappointed With 17% Slide - Yahoo Finance
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
HUMA INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $00,000 In HUMA To Contact Him Directly To Discuss Their Options - PR Newswire
Humacyte announces publication of results on ATEV - TipRanks
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery - The Manila Times
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial - EIN News
Humacyte CEO Laura Niklason buys shares worth $7,978 - Investing.com
Humacyte CEO Laura Niklason buys shares worth $7,978 By Investing.com - Investing.com UK
Humacyte director Brady Dougan buys $7,978 in common stock By Investing.com - Investing.com UK
Humacyte CEO Laura Niklason sells $6.6m in common stock By Investing.com - Investing.com Nigeria
Humacyte CEO Laura Niklason sells $6.6m in common stock - Investing.com India
Humacyte director Brady Dougan sells shares worth $6.6 million By Investing.com - Investing.com Nigeria
Humacyte director Brady Dougan sells shares worth $6.6 million - Investing.com
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Humacyte, Inc. (HUMA) - EIN News
HUMA LAWSUIT ALERT: Levi & Korsinsky LLP Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - TipRanks
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - Business Wire
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):